TABLE 1.
Frequency of oncogenic alterations in NSCLC patients in China and the United States
| Frequency of oncogenic alterations | ||||
|---|---|---|---|---|
| Driver gene | Zhou et al. [18, 19, 20] | Xing et al. [21] | Chen et al. [22] | The United States [26, 29] |
| EGFR | 39.0% | 57.7% | 50.9% | 17.2% |
| ALK | 5.5% | 2.4% | 4.3% | 3.1% |
| KRAS | 8.0% | 10.3% | 7.4% | 30.8% |
| ROS1 | 2.1% | 0.6% | 0.6% | 1.0% |
| BRAF | 0.6% | 1.1% | 1.1% | 5.0% |
| RET | 1.5% | 0.6% | 1.1% | 1.7% |
| HER2 | 1.7% | 4.3% | 1.9% | 3.0% |
Abbreviations: ALK, anaplastic lymphoma kinase; BRAF, BRaf proto‐oncogene, serine/threonine kinase; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; KRAS, kirsten rat sarcoma viral oncogene; NSCLC, non‐small cell lung cancer; RET, transfection proto‐oncogene gene; ROS1, ROS proto‐oncogene 1,receptor tyrosine kinase.